Verweij J., Clavel M., Chevalier B.: Paclitaxel (Taxol™) and docetaxel (Taxotere®): Not simply two of a kind . Ann Oncol5:495-505, 1994
2.
Rowinsky EK, Donehower RC: Vinca alkaloids and epipodophyllotoxins, in Perry MC (ed): The Chemotherapy Source Book. Baltimore, MD, Williams & Wilkins, pp 359-383, 1992
3.
Lavelle F., Bissery MC, Combeau C., et al: Preclinical evaluation of docetaxel (Taxotere). Semin Oncol22:3-16, 1995 (suppl 4)
4.
Pazdur R., Kudelka AP, Kavanagh PR, et al: The taxoids: Paclitaxel (Taxole) and docetaxel (Taxotere®). Cancer Treat Rev l 9:351-386, 1993
5.
Ravdin PM, Valero V.: Review of docetaxel (Taxotere), a highly active new agent for the treatment of metastatic breast cancer. Semin Oncol22:17-21, 1995 (suppl 4)
6.
Schrijvers D. , Wanders J., Dirix L., et al: Coping with toxicities of docetaxel (Taxotere®). Ann Oncol4:610-611, 1993
7.
Wanders J., Schrijvers D., Bruntsch U., et al: The EORTC-ECTG experience with acute hypersensitivity reactions (HSR) in Taxotere® studies. Proc Am Soc Clin Oncol12:73, 1993 (abstr)
8.
New P.: Neurotoxicity of Taxotere®. Proc Am Assoc Cancer Res34:233, 1993 (abstr)
9.
Oulid-Aissa D., Behar A., Spielmann M., et al: Management of fluid retention syndrome in patients treated with Taxotere® (docetaxel): Effect of premedication. Proc Am Soc Clin Oncol13:465, 1994 (abstr)
10.
Blaney S., Seibel N., O'Brien M., et al: A phase I study of Taxotere in pediatric patients. Proc Am Assoc Cancer Res35:211, 1994 (abstr)
